HMG-I/HMG-Y CRISPR/Cas9 KO Plasmid (h): sc-402396

Overview

HMGA1 encodes the architectural chromatin proteins HMG-I and HMG-Y, AT-hook DNA-binding factors that reshape chromatin to modulate transcription, replication, and higher-order genome organization. By binding AT-rich regulatory regions, HMGA1 facilitates enhanceosome assembly and influences signaling-linked transcriptional programs including cell-cycle control, DNA damage responses, and inflammatory pathways such as NF-κB-dependent gene expression. Dysregulated HMGA1 expression or activity is associated with altered cellular plasticity, proliferation, and metabolic adaptation, and it is frequently studied in the context of oncogenic transcriptional networks and tumor progression. HMGA1 also impacts chromatin accessibility at lineage-specific loci, making it a useful node for investigating epigenetic regulation and stress-responsive gene expression.

HMG-I/HMG-Y CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the HMGA1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the HMGA1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the HMGA1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HMG-I/HMG-Y protein expression.

This CRISPR knockout system enables efficient generation of HMGA1-deficient cell models for investigation of HMG-I/HMG-Y signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting HMGA1 exon(s) critical for HMG-I/HMG-Y function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple HMGA1 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by HMG-I/HMG-Y CRISPR/Cas9 KO Plasmid (h) and HMG-I/HMG-Y CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the HMGA1 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by HMG-I/HMG-Y HDR Plasmid (h) and HMG-I/HMG-Y HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by HMGA1 homology arms to support homology-directed repair at defined HMGA1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.